Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Wiggin

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Oncotarget|November 19, 2016
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancerEvelyn Kidess-Sigal, Haiyan E Liu, Melanie M Triboulet, et al.
Nature Biotechnology|October 11, 2008
The potential and challenges of nanopore sequencingDaniel Branton, David W Deamer, Andre Marziali, et al.
Cell Reports|May 14, 2022
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Oncotarget|November 19, 2016
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancerEvelyn Kidess-Sigal, Haiyan E Liu, Melanie M Triboulet, et al.
Nature Biotechnology|October 11, 2008
The potential and challenges of nanopore sequencingDaniel Branton, David W Deamer, Andre Marziali, et al.
Cell Reports|May 14, 2022
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Biorxiv : the Preprint Server for Biology|May 11, 2021
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsKathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Pageof 2